Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07281768 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 66 participants, started 2026-07-14 and due to reach its primary completion in 2030-07. Interventions recorded: Oxaliplatin; Capecitabine; Cemiplimab; Fianlimab; REGN7075. Conditions listed: Colorectal Cancer. Primary outcome: Pathologic complete response (pCR) rate. Colorectal eligibility wording from the registry: "* Rectal cancer (with tumor tissue present at or below the peritoneal reflection) as determined by MRI pelvis or endoscopic ultrasound". Sites: United States. No results are recorded here; the registry entry is the source.